(Total Views: 505)
Posted On: 09/14/2024 11:42:17 AM
Post# of 148878
Clinical trials
CytoDyn has conducted clinical trials to evaluate leronlimab's effectiveness in treating NASH:
Phase 2 trial: A Phase 2 trial found that leronlimab significantly improved both the primary and secondary endpoints for NASH. The primary endpoint was proton density fat fraction (PDFF), an MRI biomarker for fatty deposition. The secondary endpoint was cT1, an iron-corrected T1 mapping indicator of fibrosis and liver inflammation.
CytoDyn has conducted clinical trials to evaluate leronlimab's effectiveness in treating NASH:
Phase 2 trial: A Phase 2 trial found that leronlimab significantly improved both the primary and secondary endpoints for NASH. The primary endpoint was proton density fat fraction (PDFF), an MRI biomarker for fatty deposition. The secondary endpoint was cT1, an iron-corrected T1 mapping indicator of fibrosis and liver inflammation.
(5)
(0)Scroll down for more posts ▼
